These results indicated that agonist-activated MAPK/RSK pathway significantly contributes to the regulation of eIF4B and S6 phosphorylation, and PDCD4 levels in breast cancer cells with activating mutations in this pathway. Here, RPS6KA2 is linked to breast carcinoma.